Background Concerns remain about the safety of adding long-acting β2-agonists to inhaled
glucocorticoids for the treatment of asthma. In a postmarketing safety study mandated by the …

Objective and background: Budesonide/formoterol 160/4.5 µg, two inhalations bd, is an
effective and well‐tolerated maintenance therapy for patients not controlled on inhaled …

This paper reviews the results from 3 randomized, double-blind, placebo-controlled,
multicenter studies that assessed the efficacy and safety of once-and twice-daily dosing of …

We aimed to compare the efficacy and safety of budesonide/formoterol (Symbicort®) with
budesonide alone (Pulmicort®) or budesonide (Pulmicort) and formoterol (Oxis®) …

Background Combination therapy with inhaled corticosteroids (ICSs) and long-acting β 2-
agonists (LABAs), or treatment with high doses of ICSs alone improves asthma control when …

Few studies have evaluated inhaled corticosteroid (ICS)/long-acting beta< sub> 2-
adrenergic agonist combination therapy in asthmatic children. This study was designed to …

OBJECTIVE: To compare the safety of budesonide inhalation suspension (BIS) with placebo
in infants 6 to 12 months of age with mild to moderate persistent asthma or recurrent …

Background In a previous study, we found that two years of treatment with an inhaled
corticosteroid, budesonide, was more effective than treatment with an inhaled β2-agonist …

Abstract▴ Current evidence suggests that the addition of the long acting inhaled β 2-agonist
formoterol to low or moderate doses of the inhaled corticosteroid budesonide is effective in …

Background Inhaled corticosteroids are available in the form of a suspension for
nebulisation, although the role of this mode of therapy in the treatment of chronic asthma is …